Serotonin 5-HT2A receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism

Journal of Neurochemistry

Volumn 99, Issue 4, 2006, Pages 1164-1175

  Parrish, Jason C ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

2 arachidonoylglycerol; Endocannabinoid; Hallucinogen; Phospholipase C; Phospholipase D; Serotonin2a receptor

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; 2 ARACHIDONOYLGLYCEROL; 5 METHOXY N,N DIMETHYLTRYPTAMINE; ACYLGLYCEROL LIPASE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ARACHIDONIC ACID; BROLAMFETAMINE; CALCIMYCIN; CALCIUM IONOPHORE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIACYLGLYCEROL; ENDOCANNABINOID; ENZYME INHIBITOR; FLUOROPHOSPHATE; LIPID; LIPOPROTEIN LIPASE; MESCALINE; METHYLARACHIDONOYLFLUOROPHOSPHONATE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PSILOCIN; SEROTONIN; SEROTONIN 2A RECEPTOR; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; LIQUID SCINTILLATION COUNTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ARACHIDONIC ACIDS; BRAIN; ENDOCANNABINOIDS; ENZYME INHIBITORS; GLYCERIDES; IONOPHORES; MICE; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 33750456999     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04173.x     Document Type: Article

References (54)

1. Amtmann E. (1996) The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp. Clin. Res. 22, 287-294.
2. Bae Y. S., Lee T. G., Park J. C., Hur J. H., Kim Y., Heo K., Kwak J. Y., Suh P. G. and Ryu S. H. (2003) Identification of a compound that directly stimulates phospholipase C activity. Mol. Pharmacol. 63, 1043-1050.
3. Berg K. A., Maayani S., Goldfarb J., Scaramellini C., Leff P. and Clarke W. P. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54, 94-104.
4. Bisogno T., Melck D., De P. L. and Di Marzo V. (1999) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113-2119.
5. Bisogno T. Howell F. Williams G. et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463-468.
6. Cadogan A. K., Alexander S. P., Boyd E. A. and Kendall D. A. (1997) Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. 69, 1131-1137.
7. Carrier E. J., Kearn C. S., Barkmeier A. J., Breese N. M., Yang W., Nithipatikom K., Pfister S. L., Campbell W. B. and Hillard C. J. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65, 999-1007.
8. Carter O. L., Burr D. C., Pettigrew J. D., Wallis G. M., Hasler F. and Vollenweider F. X. (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J. Cogn. Neurosci. 17, 1497-1508.
9. Conn P. J. and Sanders-Bush E. (1986) Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J. Neurosci. 6, 3669-3675.
10. Darmani N. A. (2001) Cannabinoids of diverse structure inhibit two DOI-induced 5-HT (2A) receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav. 68, 311-317.
11. Darmani N. A. and Pandya D. K. (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J. Neural Transm. 107, 931-945.
12. Di Marzo V., Breivogel C. S., Tao Q., Bridgen D. T., Razdan R. K., Zimmer A. M., Zimmer A. and Martin B. R. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB (1) cannabinoid receptor knockout mice: evidence for non-CB (1), non-CB (2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444.
13. Dinh T. P., Kathuria S. and Piomelli D. (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 66, 1260-1264.
14. Florin-Christensen J., Florin-Christensen M., Delfino J. M., Stegmann T. and Rasmussen H. (1992) Metabolic fate of plasma membrane diacylglycerols in NIH 3T3 fibroblasts. J. Biol. Chem. 267, 14 783-14 789.
15. Freund T.-F., Katona I. and Piomelli D. (2003) Role of endogenous cannobinoids in synaptic signaling. Physiol. Rev. 83, 1017-1066.
16. Gifford A. N. and Ashby C. R. Jr (1996) Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277, 1431-1436.
17. Giuffrida A., Parsons L. H., Kerr T. M., Rodriguez F. F. de, Navarro M. and Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363.
18. Gorzalka B. B., Hill M. N. and Sun J. C. (2005) Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. Eur. J. Pharmacol. 516, 28-33.
19. Gu Q. (2002) Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience 111, 815-835.
20. Gulyas A. I., Cravatt B. F., Bracey M. H., Dinh T. P., Piomelli D., Boscia F. and Freund T. F. (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci. 20, 441-458.
21. Hashimotodani Y., Ohno-Shosaku T., Tsubokawa H., Ogata H., Emoto K., Maejima T., Araishi K., Shin H. S. and Kano M. (2005) Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron 45, 257-268.
22. Hohmann A. G., Suplita R. L., Bolton N. M. et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-1112.
23. Hoyer D., Hannon J. P. and Martin G. R. (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533-554.
24. Jan C. R., Wu S. N. and Tseng C. J. (1999) The ether lipid ET-18-OCH3 increases cytosolic Ca2+ concentrations in Madin Darby canine kidney cells. Br. J. Pharmacol. 127, 1502-1510.
25. Jung K. M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., Mackie K. and Piomelli D. (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol. Pharmacol. 68, 1196-1202.
26. Kehne J. H., Baron B. M., Carr A. A. et al. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277, 968-981.
27. Kim J., Isokawa M., Ledent C. and Alger B. E. (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22, 10 182-10 191.
28. Kreitzer A. C. and Regehr W. G. (2001a) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727.
29. Kreitzer A. C. and Regehr W. G. (2001b) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 21, RC174.
30. Krjukova J., Holmqvist T., Danis A. S., Akerman K. E. and Kukkonen J. P. (2004) Phospholipase C activator m-3M3FBS affects Ca2+ homeostasis independently of phospholipase C activation. Br. J. Pharmacol. 143, 3-7.
31. 2 Signaling Pathway. (Ph.D Thesis) West Lafayette, IN: Purdue University,.
32. Kurrasch-Orbaugh D. M., Parrish J. C., Watts V. J. and Nichols D. E. (2003a) A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J. Neurochem. 86, 980-991.
33. Kurrasch-Orbaugh D. M., Watts V. J., Barker E. L. and Nichols D. E. (2003b) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 304, 229-237.
34. Maejima T., Hashimoto K., Yoshida T., Aiba A. and Kano M. (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475.
35. Maejima T., Oka S., Hashimotodani Y., Ohno-Shosaku T., Aiba A., Wu D., Waku K., Sugiura T. and Kano M. (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J. Neurosci. 25, 6826-6835.
36. Meltzer H. Y. (1995) The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J. Clin. Psychopharmacol. 15, 2S-3S.
37. Moriyama T., Urade R. and Kito M. (1999) Purification and characterization of diacylglycerol lipase from human platelets. J. Biochem. (Tokyo) 125, 1077-1085.
38. Nakazi M., Bauer U., Nickel T., Kathmann M. and Schlicker E. (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 361, 19-24.
39. Ohno-Shosaku T., Maejima T. and Kano M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738.
40. Ohno-Shosaku T., Matsui M., Fukudome Y., Shosaku J., Tsubokawa H., Taketo M. M., Manabe T. and Kano M. (2003) Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur. J. Neurosci. 18, 109-116.
41. Perry D. K., Hand W. L., Edmondson D. E. and Lambeth J. D. (1992) Role of phospholipase D-derived diacylglycerol in the activation of the human neutrophil respiratory burst oxidase. Inhibition by phosphatidic acid phosphohydrolase inhibitors. J. Immunol. 149, 2749-2758.
42. Reibaud M., Obinu M. C., Ledent C., Parmentier M., Bohme G. A. and Imperato A. (1999) Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur. J. Pharmacol. 379, R1-R2.
43. Robertson D. N., Johnson M. S., Moggach L. O., Holland P. J., Lutz E. M. and Mitchell R. (2003) Selective interaction of ARF1 with the carboxy-terminal tail domain of the 5-HT2A receptor. Mol. Pharmacol. 64, 1239-1250.
44. Saario S. M., Savinainen J. R., Laitinen J. T., Jarvinen T. and Niemi R. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 67, 1381-1387.
45. Saucier C. and Albert P. R. (1997) Identification of an endogenous 5-hydroxytryptamine2A receptor in NIH-3T3 cells: agonist-induced down-regulation involves decreases in receptor RNA and number. J. Neurochem. 68, 1998-2011.
46. Schlicker E., Timm J. and Gothert M. (1996) Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn Schmiedebergs Arch. Pharmacol. 354, 791-795.
47. Schlicker E., Timm J., Zentner J. and Gothert M. (1997) Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 356, 583-589.
48. Sorensen S. M., Kehne J. H., Fadayel G. M., Humphreys T. M., Ketteler H. J., Sullivan C. K., Taylor V. L. and Schmidt C. J. (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266, 684-691.
49. Steffens M., Szabo B., Klar M., Rominger A., Zentner J. and Feuerstein T. J. (2003) Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience 120, 455-465.
50. Steffens M., Engler C., Zentner J. and Feuerstein T. J. (2004) Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br. J. Pharmacol. 141, 1193-1203.
51. Varvel S. A. and Lichtman A. H. (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J. Pharmacol. Exp. Ther. 301, 915-924.
52. Vollenweider F. X., Vollenweider-Scherpenhuyzen M. F., Babler A., Vogel H. and Hell D. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897-3902.
53. Williams G. V., Rao S. G. and Goldman-Rakic P. S. (2002) The physiological role of 5-HT2A receptors in working memory. J. Neurosci. 22, 2843-2854.
54. Wilson R. I. and Nicoll R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.